Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

High-Throughput Ca2+ Flux Assay To Monitor Cyclic Nucleotide-Gated Channel Activity and Characterize Achromatopsia Mutant Channel Function.

Jacobson MA, Jones LJ, Colussi DJ, Tanaka JC.

ACS Chem Neurosci. 2019 Jul 24. doi: 10.1021/acschemneuro.9b00231. [Epub ahead of print]

PMID:
31290651
2.

Identification of Novel Inhibitors of DLK Palmitoylation and Signaling by High Content Screening.

Martin DDO, Kanuparthi PS, Holland SM, Sanders SS, Jeong HK, Einarson MB, Jacobson MA, Thomas GM.

Sci Rep. 2019 Mar 6;9(1):3632. doi: 10.1038/s41598-019-39968-8.

3.

Patient-Derived Phenotypic High-Throughput Assay to Identify Small Molecules Restoring Lysosomal Function in Tay-Sachs Disease.

Colussi DJ, Jacobson MA.

SLAS Discov. 2019 Mar;24(3):295-303. doi: 10.1177/2472555218814538. Epub 2019 Jan 7.

PMID:
30616450
4.

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ.

Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25.

PMID:
30454645
5.

Assessment and Management of Hypotension in the Elderly Patient.

Kataria HL, Jacobson MA.

J Emerg Trauma Shock. 2018 Jul-Sep;11(3):221-224. doi: 10.4103/JETS.JETS_18_17.

6.

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI.

Pero JE, Rossi MA, Kelly MJ 3rd, Lehman HD, Layton ME, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, Kuo Y, Joyce LA, Sherer EC, Jacobson MA.

ACS Med Chem Lett. 2016 Jan 10;7(3):312-7. doi: 10.1021/acsmedchemlett.5b00459. eCollection 2016 Mar 10.

7.

Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.

Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA.

AIDS. 2016 Jun 19;30(10):1573-82. doi: 10.1097/QAD.0000000000001072.

8.

Ribosome-Templated Azide-Alkyne Cycloadditions: Synthesis of Potent Macrolide Antibiotics by In Situ Click Chemistry.

Glassford I, Teijaro CN, Daher SS, Weil A, Small MC, Redhu SK, Colussi DJ, Jacobson MA, Childers WE, Buttaro B, Nicholson AW, MacKerell AD Jr, Cooperman BS, Andrade RB.

J Am Chem Soc. 2016 Mar 9;138(9):3136-44. doi: 10.1021/jacs.5b13008. Epub 2016 Feb 26.

9.

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis.

Layton ME, Reif AJ, Hartingh TJ, Rodzinak K, Dudkin V, Wang C, Arrington K, Kelly MJ 3rd, Garbaccio RM, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Tang C, Kuo Y, Jacobson MA.

Bioorg Med Chem Lett. 2016 Feb 15;26(4):1260-4. doi: 10.1016/j.bmcl.2016.01.021. Epub 2016 Jan 11.

PMID:
26810316
10.

Improving Diabetes Care for Hospice Patients.

Lee SJ, Jacobson MA, Johnston CB.

Am J Hosp Palliat Care. 2016 Jul;33(6):517-9. doi: 10.1177/1049909115578386. Epub 2015 Apr 7.

PMID:
25852204
11.

Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts.

Carter RL, Grisanti LA, Yu JE, Repas AA, Woodall M, Ibetti J, Koch WJ, Jacobson MA, Tilley DG.

Pharmacol Res Perspect. 2014 Feb;2(1). doi: 10.1002/prp2.24.

12.

Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.

Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):25-32. doi: 10.1097/QAI.0000000000000095.

13.

The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.

Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA; A5030 Study Team.

PLoS One. 2013 Nov 15;8(11):e78676. doi: 10.1371/journal.pone.0078676. eCollection 2013.

14.

Cytomegalovirus viraemia in the modern antiretroviral era(*).

Jacobson M, Lurain N, Hunt P.

HIV Med. 2011 Aug;12(7):387-8. doi: 10.1111/j.1468-1293.2010.00899.x. No abstract available.

15.

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG.

J Infect Dis. 2011 May 15;203(10):1474-83. doi: 10.1093/infdis/jir060.

16.

Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17 cell depletion and poor systemic CMV-specific T cell responses.

Hartigan-O'Connor DJ, Jacobson MA, Tan QX, Sinclair E; Studies of Ocular Complications of AIDS Research Group.

Clin Infect Dis. 2011 Feb 1;52(3):409-17. doi: 10.1093/cid/ciq112. Epub 2010 Dec 28.

17.

Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration.

Parmentier-Batteur S, O'Brien JA, Doran S, Nguyen SJ, Flick RB, Uslaner JM, Chen H, Finger EN, Williams TM, Jacobson MA, Hutson PH.

Neuropharmacology. 2012 Mar;62(3):1453-60. doi: 10.1016/j.neuropharm.2010.11.013. Epub 2010 Nov 26.

PMID:
21112344
18.

Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor.

Garbaccio RM, Brnardic EJ, Fraley ME, Hartman GD, Hutson PH, O'Brien JA, Magliaro BC, Uslaner JM, Huszar SL, Fillgrove KL, Small JH, Tang C, Kuo Y, Jacobson MA.

ACS Med Chem Lett. 2010 Jul 12;1(8):406-10. doi: 10.1021/ml100115a. eCollection 2010 Nov 11.

19.

The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.

Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, Sur C.

Mol Pharmacol. 2010 Oct;78(4):648-57. doi: 10.1124/mol.110.065771. Epub 2010 Jul 21.

PMID:
20660086
20.

3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts.

Brnardic EJ, Fraley ME, Garbaccio RM, Layton ME, Sanders JM, Culberson C, Jacobson MA, Magliaro BC, Hutson PH, O'Brien JA, Huszar SL, Uslaner JM, Fillgrove KL, Tang C, Kuo Y, Sur SM, Hartman GD.

Bioorg Med Chem Lett. 2010 May 15;20(10):3129-33. doi: 10.1016/j.bmcl.2010.03.089. Epub 2010 Mar 31.

PMID:
20409708
21.

Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team.

HIV Clin Trials. 2009 May-Jun;10(3):143-52. doi: 10.1310/hct1003-143.

22.

Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.

Uslaner JM, Parmentier-Batteur S, Flick RB, Surles NO, Lam JS, McNaughton CH, Jacobson MA, Hutson PH.

Neuropharmacology. 2009 Oct-Nov;57(5-6):531-8. doi: 10.1016/j.neuropharm.2009.07.022. Epub 2009 Jul 21.

PMID:
19627999
23.

Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients.

Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C.

PLoS One. 2009;4(4):e5277. doi: 10.1371/journal.pone.0005277. Epub 2009 Apr 17.

24.

Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.

Wolkenberg SE, Zhao Z, Wisnoski DD, Leister WH, O'Brien J, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Gibson C, Ma BK, Polsky-Fisher SL, Lindsley CW, Hartman GD.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1492-5. doi: 10.1016/j.bmcl.2009.01.015. Epub 2009 Jan 10.

PMID:
19181525
25.

Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors.

Zhao Z, Leister WH, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Lindsley CW, Wolkenberg SE.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1488-91. doi: 10.1016/j.bmcl.2008.12.115. Epub 2009 Jan 9.

PMID:
19179073
26.

A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).

Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK.

Vaccine. 2009 Mar 4;27(10):1540-8. doi: 10.1016/j.vaccine.2009.01.006. Epub 2009 Jan 23.

PMID:
19168107
27.

The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.

Smith SM, Uslaner JM, Yao L, Mullins CM, Surles NO, Huszar SL, McNaughton CH, Pascarella DM, Kandebo M, Hinchliffe RM, Sparey T, Brandon NJ, Jones B, Venkatraman S, Young MB, Sachs N, Jacobson MA, Hutson PH.

J Pharmacol Exp Ther. 2009 Mar;328(3):921-30. doi: 10.1124/jpet.108.147884. Epub 2008 Dec 16.

PMID:
19088300
28.

Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice.

Björklund O, Halldner-Henriksson L, Yang J, Eriksson TM, Jacobson MA, Daré E, Fredholm BB.

Physiol Behav. 2008 Dec 15;95(5):668-76. doi: 10.1016/j.physbeh.2008.09.018. Epub 2008 Sep 27.

PMID:
18930070
29.

Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic.

Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):231-3. doi: 10.1097/QAI.0b013e318183a947. No abstract available.

PMID:
18820536
30.

Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS.

Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E; Studies of Ocular Complications of AIDS Research Group.

Clin Infect Dis. 2008 Feb 1;46(3):458-66. doi: 10.1086/525853.

31.

Papulonecrotic eruption in a 44-year-old-man.

Jacobson MA, Pollack RB, Maize JC Jr.

South Med J. 2007 Dec;100(12):1221-2.

PMID:
18090966
32.

Loss of T cell responses following long-term cryopreservation.

Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, Tan QX, Custer B, Harris JM, Jacobson MA, McCune JM, Martin JN, Hecht FM, Deeks SG, Norris PJ.

J Immunol Methods. 2007 Sep 30;326(1-2):93-115. Epub 2007 Aug 8.

33.

Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects.

Pott GB, Sailer CA, Porat R, Peskind RL, Fuchs AC, Angel JB, Skolnik PR, Jacobson MA, Giordano MF, Lebeaut A, Grint PC, Dinarello CA, Shapiro L.

Eur Cytokine Netw. 2007 Jun;18(2):49-58. Epub 2007 Jun 26.

34.

Antibiotic use in the treatment of soft tissue abscesses: a survey of current practice.

Rajendran PM, Young DM, Maurer T, Chambers HF, Jacobson MA, Harris HW.

Surg Infect (Larchmt). 2007 Apr;8(2):237-8. No abstract available.

PMID:
17437370
35.
36.

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors.

Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK.

Circulation. 2007 Mar 27;115(12):1581-90. Epub 2007 Mar 12.

PMID:
17353435
37.

Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.

Zhao Z, Wisnoski DD, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Wittman M, Ha SN, Schaffhauser H, Sur C, Pettibone DJ, Duggan ME, Conn PJ, Hartman GD, Lindsley CW.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1386-91. Epub 2006 Dec 3.

PMID:
17210250
38.

Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.

Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA; Studies of Ocular Complications of AIDS Research Group.

J Infect Dis. 2006 Dec 1;194(11):1537-46. Epub 2006 Oct 26.

PMID:
17083038
39.

Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides.

Zhao Z, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Wolkenberg SE, Lindsley CW.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5968-72. Epub 2006 Sep 20.

PMID:
16987662
40.

Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.

Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA.

J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10. Epub 2006 Sep 19.

PMID:
16985166
41.

Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides.

Lindsley CW, Zhao Z, Leister WH, O'Brien J, Lemaire W, Williams DL Jr, Chen TB, Chang RS, Burno M, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Tsou NN, Duggan ME, Conn PJ, Hartman GD.

ChemMedChem. 2006 Aug;1(8):807-11. No abstract available.

PMID:
16902933
42.

Cutaneous involvement by Burkitt lymphoma.

Jacobson MA, Hutcheson AC, Hurray DH, Metcalf JS, Thiers BH.

J Am Acad Dermatol. 2006 Jun;54(6):1111-3. No abstract available.

PMID:
16713488
43.

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP.

Vaccine. 2006 Jun 19;24(25):5311-9. Epub 2006 May 2.

PMID:
16701925
44.

Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.

Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP.

J Clin Virol. 2006 Mar;35(3):332-7. Epub 2006 Jan 18.

PMID:
16387547
45.

Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS.

Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F.

HIV Clin Trials. 2005 Sep-Oct;6(5):246-53.

PMID:
16306031
46.

The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.

Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ; ACTG 379 Study Team.

HIV Clin Trials. 2005 May-Jun;6(3):136-46.

PMID:
16192248
47.

Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.

Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL; Studies of Ocular Complications of AIDS Research Group.

Ophthalmology. 2005 May;112(5):771-9.

PMID:
15878056
48.

Editorial comment: failure of HAART to reconstitute CMV-specific protective immunity.

Jacobson MA.

AIDS Read. 2005 Apr;15(4):188. No abstract available.

PMID:
15844239
49.

Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.

D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA.

J Clin Immunol. 2005 Mar;25(2):106-15.

PMID:
15821887
50.

Supplemental Content

Loading ...
Support Center